• Senseonics initiated its first-in-human feasibility study of Freedom, an investigational continuous glucose monitoring system.
• Freedom is designed to provide one-year monitoring through direct Bluetooth communication with mobile devices, eliminating an external on-body transmitter.
• Preclinical testing completed in the second quarter of 2026 covered approximately seven weeks and more than 18,500 communication data points.
• The preferred antenna design achieved 100% communication success within the target distance, supporting selection of a configuration for human evaluation.
• The study will inform a pivotal trial expected to begin in 2027, with a potential commercial launch targeted for 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260800PRIMZONEFULLFEED9851622) on October 26, 2026, and is solely responsible for the information contained therein.